Concepts
MDMA-Assisted Therapy
Research notes
Context, reporting, and structured background for this dossier.
MDMA-assisted therapy is a treatment model combining MDMA administration with structured psychotherapy for PTSD. Typically 2-3 sessions of 8 hours each. Developed primarily by MAPS over 30+ years. Rejected by the FDA in August 2024.
Related reporting
Recent SCM reporting that overlaps this dossier’s company, program, or governance record.
- Where MAPS Is Now
After the FDA rejected Lykos' MDMA therapy application, MAPS shifted toward policy, education, and the long game.
- Trump Moves Qualifying Medical Marijuana Products to Schedule III as Broader Rescheduling Fight Continues
The Justice Department says FDA-approved marijuana products and qualifying state-licensed medical marijuana products are moving into Schedule III immediately, but broader marijuana rescheduling, and much of the tax relief investors are betting on, still depends on a separate June hearing and who actually qualifies.
- Week in Review: The EPIsoDE Trial, a $1.2B Acquisition, and the State of State Policy
First full week roundup.
Related entities
Other dossiers that help connect this page to the wider reporting record.
- MDMA
- Lykos Therapeutics
Lykos Therapeutics is the commercial entity that took over the MDMA-assisted therapy for PTSD approval path from MAPS and remains the focal company in the FDA midomafetamine saga.
- MAPS (Multidisciplinary Association for Psychedelic Studies)
MAPS is the nonprofit organization that incubated and sponsored the modern MDMA-assisted therapy for PTSD program before the commercial approval effort moved into Lykos Therapeutics.
- FDA
The U.S. Food and Drug Administration is the gatekeeper for psychedelic drug development in the United States, from IND clearance through advisory committee review and any eventual approval or rejection.